|1.||Singh, Vijay Pal: 5 articles (01/2007 - 01/2004)|
|2.||Kulkarni, Shrinivas K: 5 articles (12/2005 - 01/2004)|
|3.||Patil, Chandrashekhar S: 5 articles (12/2005 - 01/2004)|
|4.||Cuzzocrea, Salvatore: 4 articles (01/2006 - 10/2003)|
|5.||Antileukotriene Working Group: 4 articles (06/2001 - 06/2001)|
|6.||Chen, Xiaoxin: 3 articles (01/2012 - 10/2004)|
|7.||Zouboulis, Christos C: 3 articles (02/2010 - 05/2003)|
|8.||Walton-Bowen, Karen: 3 articles (08/2007 - 01/2007)|
|9.||Haynes, Johnson: 2 articles (01/2015 - 06/2005)|
|10.||Bentrem, David J: 2 articles (01/2015 - 10/2008)|
|1.||Asthma (Bronchial Asthma)
02/01/2004 - "Zileuton, an inhibitor of 5-lipooxygenase, the initial enzyme in the leukotriene pathway, was marketed as a new treatment for asthma. "
05/01/2007 - "This study was conducted to assess the safety and efficacy of zileuton controlled release [CR] 1,200 mg BID added to usual care (UC) in 926 patients with moderate asthma (619 patients randomized to zileuton CR and 307 to placebo). "
04/01/1999 - "Zileuton, a leukotriene synthesis inhibitor in the management of chronic asthma. "
01/01/1997 - "Zileuton, a leukotriene synthesis inhibitor, has been shown to improve airway function and reduce asthma-symptoms, although there is some concern over liver toxicity. "
01/01/2007 - "In this study, 2458 patients with asthma received zileuton 600mg four times daily in addition to usual asthma care, and 489 patients were treated with usual asthma care only. "
01/01/2013 - "This study aimed to evaluate the effects of zileuton on bronchial hyperresponsiveness, airway inflammation and airway smooth muscle (ASM) remodeling. "
01/01/2013 - "Zileuton had beneficial effects on pulmonary function, airway inflammation and ASM remodeling in the OA-zileuton group compared to the OA-saline group. "
09/01/1999 - "Due to its induction of hepatic enzyme activity zileuton is not available in Poland, but it is important agent in evaluation of the leukotriene inhibitors in some models of inflammation. "
04/01/2007 - "In a number of clinical trials, zileuton has been shown to improve airway function and inflammation, asthma symptom control and quality of life in asthmatics. "
01/01/2015 - "In the current study, we inhibited 5-LO by dietary administration of Zileuton in the APCΔ468 mouse model of polyposis and analyzed the effect of in vivo 5-LO inhibition on tumor-associated and systemic inflammation. "
|3.||Atopic Dermatitis (Atopic Eczema)
08/01/2001 - "Further studies with larger number of dogs are needed to evaluate the efficacy of zileuton as treatment for canine atopic dermatitis."
08/01/2001 - "Double-blinded, placebo-controlled, cross-over pilot study on the efficacy of zileuton for canine atopic dermatitis."
12/01/1999 - "To examine the efficacy of zileuton in treating atopic dermatitis by measuring both subjective and objective outcome parameters. "
08/01/2001 - "Zileuton and atopic dermatitis."
12/01/1999 - "In this pilot study, zileuton showed efficacy in significantly improving the symptoms and objective skin findings seen in atopic dermatitis. "
|4.||Chronic Obstructive Pulmonary Disease (COPD)
04/01/2007 - "In addition, zileuton has shown promise in a number of other conditions, including upper airway inflammatory conditions, dermatological disease and chronic obstructive pulmonary disease. "
02/01/2011 - "Randomized double-blind, placebo-controlled, parallel group study of zileuton 600 mg orally, 4 times daily versus placebo for 14 days starting within 12 hours of hospital admission for COPD exacerbation. "
02/01/2011 - "Randomized trial of zileuton for treatment of COPD exacerbations requiring hospitalization."
02/01/2011 - "While oral zileuton during COPD exacerbations that require hospital admission is safe and reduces urinary LTE(4) levels, we found no evidence suggesting that this intervention shortened hospital stay, with the limitation that our sample size may have been insufficient to detect a modest but potentially meaningful clinical improvement."
02/01/2011 - "We sought to test the safety and efficacy of adding oral zileuton (a 5-lipoxygenase inhibitor) to usual treatment for acute exacerbations of COPD requiring hospitalization. "
12/01/1995 - "The efficacy of three such inhibitors that have been in clinical trials (zileuton, A-78773 and ZD2138) were evaluated in: 1) ex vivo whole blood assay, 2) dermal Arthus reaction, and 3) functional airway response. "
03/01/1991 - "ED50 of 2 mg/kg. Zileuton was highly effective in preventing 6-sulfidopeptide LT formation in the rat peritoneal cavity triggered by an antigen-antibody reaction with an ED50 of 3 mg/kg. In experimental models of inflammation, zileuton significantly reduced arachidonic-acid induced mouse ear edema (ED50 = 31 mg/kg) and also attenuated inflammatory cell accumulation in the rat pleural Arthus reaction. "
|1.||Arachidonate 5-Lipoxygenase (5 Lipoxygenase)
|9.||Leukotriene Antagonists (Leukotriene Receptor Antagonists)
|10.||Arachidonic Acid (Vitamin F)
|4.||Drug Therapy (Chemotherapy)